Newsletter | 01 February 2002 Access News 6, Focus on Malaria, February 2002 HIV/AIDS INTELLECTUAL PROPERTY AND TRADE MALARIA TROPICAL & NEGLECTED DISEASES VACCINES How much for an effective malaria treatment is the focus of this edition, as well as MSF in Burundi, Doha and a potential breakthrough, trapped in the ACCESS crisis, life with chagas and HIV and meningitis outbreaks. Read, watch, share Filter by - Any -BlogEventsFeature storyInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechStatementTechnical briefVideo Photograph by Jan-Joseph Stok Press release Press release | 26 July 2024 HIV/AIDS Pharmaceutical corporation ViiV must urgently supply HIV drug CAB-LA according to global public health needs 5 min Photo credit: MSF Press release Press release | 23 July 2024 HIV/AIDS Activists at AIDS2024 Demand: Break Gilead’s Lenacapavir Monopoly Gilead’s Price 100,000% Higher than Target Generic Price for 100% Effective Prevention Shot 3 min Technical brief | 05 June 2024 HIV/AIDS Antiretroviral Prices in 2023 Letter | 22 April 2024 Diagnostics Hepatitis C HIV/AIDS Ghana Ghana: National AIDS Control Programme letter to Danaher to reduce the price of GeneXpert test Photo credit: MSF/Martim Gray Pereira Press release Press release | 06 February 2024 HIV/AIDS Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir 5 min Technical brief | 24 November 2023 HIV/AIDS Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP) Photo credit: Njiiri Karago/MSF Press release Press release | 17 August 2023 HIV/AIDS MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA 4 min Photo credit: Jan-Joseph Stok Letter Letter | 17 August 2023 HIV/AIDS Open letter to ViiV to improve access to HIV prevention drug CAB-LA 1 min Load More
Photograph by Jan-Joseph Stok Press release Press release | 26 July 2024 HIV/AIDS Pharmaceutical corporation ViiV must urgently supply HIV drug CAB-LA according to global public health needs 5 min
Photo credit: MSF Press release Press release | 23 July 2024 HIV/AIDS Activists at AIDS2024 Demand: Break Gilead’s Lenacapavir Monopoly Gilead’s Price 100,000% Higher than Target Generic Price for 100% Effective Prevention Shot 3 min
Letter | 22 April 2024 Diagnostics Hepatitis C HIV/AIDS Ghana Ghana: National AIDS Control Programme letter to Danaher to reduce the price of GeneXpert test
Photo credit: MSF/Martim Gray Pereira Press release Press release | 06 February 2024 HIV/AIDS Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir 5 min
Technical brief | 24 November 2023 HIV/AIDS Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)
Photo credit: Njiiri Karago/MSF Press release Press release | 17 August 2023 HIV/AIDS MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA 4 min
Photo credit: Jan-Joseph Stok Letter Letter | 17 August 2023 HIV/AIDS Open letter to ViiV to improve access to HIV prevention drug CAB-LA 1 min
